Rovelizumab
Rovelizumab
Rovelizumab (pronunciation: roh-veh-LIZ-uh-mab) is a monoclonal antibody that was developed for the treatment of acute stroke. It was designed to target and neutralize the interleukin-1 beta (IL-1β), a pro-inflammatory cytokine that plays a key role in the pathogenesis of acute stroke.
Etymology
The name "Rovelizumab" is derived from the standard nomenclature for monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the prefix "Rove-" does not have a specific meaning and is used to create a unique name.
Mechanism of Action
Rovelizumab works by binding to the IL-1β, thereby preventing it from interacting with its receptor and triggering the inflammatory response that contributes to the damage caused by acute stroke.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Interleukin-1 beta: A pro-inflammatory cytokine that is produced by activated macrophages and plays a key role in the inflammatory response.
- Acute stroke: A medical condition in which poor blood flow to the brain results in cell death.
See Also
External links
- Medical encyclopedia article on Rovelizumab
- Wikipedia's article - Rovelizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski